Literature DB >> 12011256

A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas.

Marc-Antoine Belaud-Rotureau1, Marie Parrens, Pierre Dubus, Jean-Christophe Garroste, Antoine de Mascarel, Jean-Philippe Merlio.   

Abstract

Mantle cell lymphoma (MCL) diagnosis first relies on morphology and phenotype that may overlap with other B-cell lymphomas. Therefore, the demonstration of t(11;14)(q13;q32), the cytogenetic hallmark of MCL, is considered of diagnostic value. By studying a series of 35 MCL with characteristic morphology and phenotype (CD5+, CD10-, CD20+, CD23-), we have evaluated the applicability and the sensitivity of interphase fluorescence in situ hybridization (FISH) for t(11;14) detection and other techniques: (1) polymerase chain reaction (PCR) for amplification of t(11;14) genomic breakpoint, (2) competitive RT-PCR for the detection of cyclin D1 transcripts overexpression, and (3) immunohistochemistry (IHC) for cyclin D1 protein detection. Tissues from different origins were analyzed: lymph nodes (n = 24), spleen (n = 3), digestive biopsy (n = 3), tonsils (n = 3), and skin (n = 2). Interphase FISH was performed either on touch preparations (n = 11) and frozen (n = 9) or paraffin sections (n = 15). FISH analysis detected t(11;14) in 34/35 cases (97%) and demonstrated a recurrent CCND1 amplification in t(11;14)+ nuclei of the three blastoid MCL variants of our series. Genomic PCR analysis, hampered by the scattering of 11q13 breakpoints, was positive in only 13/35 cases (37%). RT-PCR analysis was applicable on nonepithelial tissues (27/35) and showed cyclin D1 transcript overexpression in all tested cases (27/35). IHC for cyclin D1 protein was performed either on frozen (n = 12) or on paraffin sections (n = 23), and its sensitivity was higher on paraffin sections (91%) than on frozen sections (25%). A cyclin D1 protein immunoreactivity was observed in 24/35 cases (69%). Our study emphasizes on the use of FISH analysis for the direct detection of t(11;14) because its applicability and sensitivity largely exceeded those of other techniques. It may also provide some informations on secondary cytogenetic changes of potential clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011256     DOI: 10.1038/modpathol.3880556

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  14 in total

1.  Mantle cell lymphoma presenting with paraproteinemia.

Authors:  Grzegorz Rymkiewicz; Monika Gos; Katarzyna Błachnio; Renata Woroniecka; Paweł Swoboda; Barbara Pieńkowska-Grela; Marika Kulińska; Anna Borawska; Przemysław Janik; Jan Walewski
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Gastrointestinal Mantle Cell Lymphoma with Varied Findings.

Authors:  Atsushi Goto; Jun Nishikawa; Shunsuke Ito; Eizaburou Hideura; Tomohiro Shirasawa; Koichi Hamabe; Shinichi Hashimoto; Takeshi Okamoto; Isao Sakaida
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 3.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

Review 4.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue.

Authors:  Roland A Ventura; Jose I Martin-Subero; Margaret Jones; Joanna McParland; Stefan Gesk; David Y Mason; Reiner Siebert
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

5.  Clear cell renal cell carcinoma: a comparative study of histological and chromosomal characteristics between primary tumors and their corresponding metastases.

Authors:  Julien Dagher; Solène-Florence Kammerer-Jacquet; Frédéric Dugay; Marion Beaumont; Alexandra Lespagnol; Laurence Cornevin; Grégory Verhoest; Karim Bensalah; Nathalie Rioux-Leclercq; Marc-Antoine Belaud-Rotureau
Journal:  Virchows Arch       Date:  2017-05-10       Impact factor: 4.064

Review 6.  Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.

Authors:  Bijal D Shah; Peter Martin; Eduardo M Sotomayor
Journal:  Cancer Control       Date:  2012-07       Impact factor: 3.302

7.  Insertion of the CCND1 gene into the IgH locus in a case of leukaemic small cell mantle lymphoma with normal chromosomes 11 and 14.

Authors:  A Aventín; J Nomdedéu; J Briones; I Espinosa; R Bordes; J Sierra
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

8.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

9.  Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach.

Authors:  Anke van Rijk; David Mason; Margaret Jones; José Cabeçadas; Mateus Crespo; Juan Cruz Cigudosa; Juan Fernando Garcia; Lorenzo Leoncini; Mario Cocco; Martin-Leo Hansmann; Anja Mottok; Christiane Copie Bergman; Maryse Baia; Dimitra Anagnostou; Evi Pouliou; Stephen Hamilton Dutoit; Mette Hjøllund Christiansen; Tim Svenstrup Poulsen; Steen Hauge Matthiesen; Jacques van Dongen; J Han van Krieken
Journal:  J Hematop       Date:  2008-08-29       Impact factor: 0.196

10.  Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization.

Authors:  Roman Kodet; Marcela Mrhalová; Lenka Krsková; Jan Soukup; Vít Campr; Tomás Neskudla; Peter Szépe; Lukás Plank
Journal:  Virchows Arch       Date:  2003-05-01       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.